Akebia Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY September 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | — |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | — |
| Operating expenses | $173.2M | $147.5M | $166.7M | $287.7M | — |
| Cost of revenue | $39.5M | $63.2M | $74.1M | $85.6M | — |
| Cash from operations | $68.0M | -$40.7M | -$23.4M | -$73.2M | — |
| Capital expenditure | $291,000 | $33,000 | $0 | $114,000 | — |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $444.3M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $436.0M |
| Total debt | $52.4M | $43.0M | $35.0M | $67.0M | — |
Shares outstanding 268.3M · Free float 93.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.